

FORM PTO-1449
MODIFIEDU.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
208250APPLICATION NO.
09/743,873INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Ho et al.FILING DATE
January 17, 2001ART UNIT
~~Unassigned~~ 1624

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		APPLICATION OR PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
B.K.	AA	5,646,131	7/8/1997	Badwan et al.	514	58	
B.K.	AB	5,610,140	3/11/1997	Goodfellow et al.	514	15	
B.K.	AC	5,606,030	2/25/1997	Emini et al.	530	404	
B.K.	AD	5,387,584	2/7/1995	Schnur	514	183	
B.K.	AE	5,087,616	2/11/1992	Myers et al.	514	21	
B.K.	AF	4,261,989	4/14/1981	Sasaki et al.	424	244	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO**
B.K.	AG	WO 96/40251	12/19/1996	WIPO				
B.K.	AH	WO 94/06750	3/31/1994	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

B.K.	AI	HAWTHORNE et al., "Liposomes as Drug Delivery Vehicles for Boron Agents," <i>J. Neurooncol.</i> , 33(1-2), 53-58 (May 1997)
B.K.	AJ	SCHACTER et al., "Clinical and Pharmacokinetic Overview of Parenteral Etoposide Phosphate," <i>Cancer Chemother. Pharmacol.</i> , 34 Suppl., S58-63 (1994)
B.K.	AK	SWEETANA et al., "Solubility Principles and Practices for Parenteral Drug Dosage Form Development," <i>PDA J. Pharm. Sci. & Tech.</i> , 50, 330 (1995)

EXAMINER

Burch K. H.

DATE CONSIDERED

9/5/02

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).